Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2023-11-08 Transaction in Own Shar…
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the purchase of 150,000 ordinary shares by the company as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement confirming the information is provided by RNS (the news service of the London Stock Exchange) confirms it is a regulatory filing, but the specific content dictates the more precise classification of POS.
2023-11-08 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is a "Transaction in Own Shares" and details the purchase of 150,000 ordinary shares as part of a previously announced "share buyback programme." This directly corresponds to the definition of a Transaction in Own Shares (share repurchase/issuance), which maps to the filing code POS. The presence of the RNS Number and the closing statement confirming RNS as the information provider confirms it is a regulatory announcement, but the specific content dictates the classification over the general RNS code.
2023-11-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is 'Transaction in Own Shares' and details the number of ordinary shares purchased by the company on a specific date (November 3, 2023) as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS), which covers company repurchases. The presence of the RNS Number and the closing statement referencing RNS confirms it is a regulatory announcement, but the specific content dictates the POS classification over the general RNS fallback.
2023-11-06 English
Autolus to present clinical data updates at ASH
Regulatory Filings Classification · 98% confidence The document is an RNS announcement (indicated by 'RNS Number : 2278S') issued by Syncona Limited regarding an update from its portfolio company, Autolus Therapeutics Plc. The content details that Autolus will present clinical data updates at the American Society of Hematology (ASH) Annual Meeting 2023. The document includes highlights of the data, quotes from management, and the full text of Autolus's original announcement regarding the presentations (oral and poster). Since this is an announcement *about* upcoming presentations and data releases, and it is structured as a regulatory news service release, it fits best under the general Regulatory Filings category (RNS), as it is not the presentation itself (IP), the earnings release (ER), or a comprehensive report (10-K/IR). It is a general regulatory update concerning corporate activity/pipeline progress.
2023-11-02 English
Autolus reports Q3 2023 Financial Results
Earnings Release Classification · 99% confidence The document is an RNS announcement from Syncona Limited, noting that its portfolio company, Autolus Therapeutics Plc, announced its operational and financial results for the quarter ended September 30, 2023. The text explicitly contains the headline 'Autolus reports Q3 2023 financial results' and includes detailed financial tables (Balance Sheet and Statements of Operations) for the three and nine months ended September 30, 2023. This content structure—a brief announcement summarizing key operational and financial metrics for a period shorter than a year, followed by detailed tables—is characteristic of an Interim/Quarterly Report (IR). Although it is an announcement *of* the results, the document itself contains the comprehensive financial data typical of an IR, rather than just a brief press release summary (ER) or a simple announcement that a report is available (RPA). Since it covers a period shorter than a year (Q3), it fits the 'Interim / Quarterly Report' definition best, even though it is distributed via RNS. Q3 2023
2023-11-02 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject is a 'Transaction in Own Shares' and details the purchase of ordinary shares by the company as part of a 'share buyback programme'. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The presence of the RNS Number and the closing statement confirming the information is provided by RNS (the news service of the London Stock Exchange) confirms it is a regulatory filing, but the specific content dictates the more precise classification of POS.
2023-11-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.